Personalized chemo test aims to improve treatment for advanced abdominal cancers
NCT ID NCT07291180
First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times
Summary
This study tests a new method called mass-based response testing (MRT) to help doctors choose the best chemotherapy drugs for patients with advanced appendix or colorectal cancer that has spread to the abdomen. The MRT device analyzes live tumor cells to see which drugs work best. The study will enroll 20 patients to see if this approach is feasible and can provide results within a week.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mass-based response testing (MRT) device
- What this could lead to
- If successful, this could lead to a way to personalize chemotherapy for each patient, potentially improving treatment effectiveness.
- What could go wrong
- This is a very small, early feasibility study with only 20 participants. The test may not always work or may not lead to better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APPENDICEAL ADENOCARCINOMA WITH PERITONEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Breath of life: new test could sniff out gut cancers before they spread
- Gut instinct: listening to bowel sounds may reveal hidden clues about surgical recovery
- Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
- Triple therapy aims to wipe out colorectal cancer before surgery